Amgen buys back an osteoporosis drug from GSK; Regeneron launches a teaching fellowship;

@FierceBiotech: For those of you just waking up and getting to work in the U.S., here's our second issue of EuroBiotech: Read | Follow @FierceBiotech

@JohnCFierce: Amgen down 1.7%. I'm going to start calling Amgen a pharma co. If it walks like a duck... | Follow @JohnCFierce

@DamianFierce: Amgen: T-Vec hits on durable response but misses on OS, its secondary endpoint. Release | Follow @DamianFierce

@EmilyMFierce: The current environment for cancer care in Europe: Infographic via Janssen | Follow @EmilyMFierce

> AbbVie ($ABBV) gets out of the way as the EU prepares for trial transparency. More

> Amgen ($AMGN) is paying partner GlaxoSmithKline ($GSK) $275 million to get the sole rights to Prolia, a fast-selling osteoporosis drug. News

> According to a report commissioned by Johnson & Johnson ($JNJ), advances in cancer therapies have transformed certain tumor types from deadly ailments to, essentially, chronic diseases. More

> Regeneron ($REGN) has launched a teaching fellowship program through which high school STEM instructors will study alongside experts from the biotech and Columbia University. Item

Medical Device News

@FierceMedDev: J&J gets a mixed verdict in a trial alleging it sold faulty vaginal mesh implants. More | Follow @FierceMedDev

@MarkHFierce: ICYMI: Biotronik may have a relatively small U.S. mkt share, but it is working hard to compete here. Story | Follow @MarkHFierce

@MichaelGFierce: The year in nanotech drug delivery. Special report | Follow @MichaelGFierce

@EmilyWFierce: Adhesive medical sensors with origami-like wires could flex and bend with the skin, say researchers at Northwestern University. News | Follow @EmilyWFierce

> RefleXion raises $11.6M in Series A funding round. More

> Holaira brings in $42M Series D to test COPD lung denervation treatment tool. Article

> Vapotherm seals $24M financing round, elects new board member. Story

Pharma News

@FiercePharma: Trending on FierceVaccines: GSK will tailor vaccine portfolio, improve access as part of wider Africa initiative. More | Follow @FiercePharma

@TracyStaton: Still best-read FiercePharma: It's a big win for Eli Lilly in multibillion-dollar Alimta patent fight. Story | Follow @TracyStaton

@EricPFierce: RT: Last year, my sister died, and I learned first-hand about life sciences' limits. Article from FierceMedicalDevices | Follow @EricPFierce

@CarlyHFierce: Amgen, GSK part on fast-selling Prolia, mostly. More | Follow @CarlyHFierce

> Meda spurns Mylan takeover bid. News

> FDA's OK of opioid overdose treatment doesn't quell backlash over Zohydro. Article

Suggested Articles

Karen DeSalvo's appointment is the latest in a string of hires that deepen the tech giant’s investment in and focus on healthcare.

Spring Bank’s hepatitis B drug, given in tandem with Gilead’s Vemlidy, tamped down on chronic disease in 23% of patients in a phase 2 study.

Gilead names Dickinson to CFO role; MedImmune CSO Herbst nabs CSO job at Pyxis; Checkmate picks up Wooldridge for CMO.